Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 936-944

  Ratai, Eva Maria ^a   Zhang, Zheng ^b   Snyder, Bradley S ^b   Boxerman, Jerrold L ^c   Safriel, Yair ^d   McKinstry, Robert C ^e   Bokstein, Felix ^f   Gilbert, Mark R ^g   Sorensen, A Gregory ^a   Barboriak, Daniel P ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Neuro Oncology Service   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti angiogenic therapy; bevacizumab; Cho; glioblastoma; magnetic resonance spectroscopy; NAA

Indexed keywords

BEVACIZUMAB; CREATINE; IRINOTECAN; N ACETYLASPARTIC ACID; TEMOZOLOMIDE;

ADULT; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; TUMOR RECURRENCE;

ANTI-ANGIOGENIC THERAPY; BEVACIZUMAB; CHO; GLIOBLASTOMA; MAGNETIC RESONANCE SPECTROSCOPY; NAA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; BRAIN NEOPLASMS; CAMPTOTHECIN; CHOLINE; CREATINE; DACARBAZINE; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879334593     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not044     Document Type: Article

References (35)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8): 2572-2578. (Pubitemid 29368260)
2. Thaker NG, McDonald PR, Zhang F, et al. Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods. 2010; 185(2): 204-212.
3. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med. 2011; 17(6): 301-312.
4. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11): 1131-1138.
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28): 4733-4740.
6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996. (Pubitemid 40349501)
7. ReardonDA, Turner S, Peters KB, et al.Areview ofVEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011; 9(4): 414-427.
8. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011; 12(5): 825-833.
9. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12(3): 233-242.
10. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7): 1277-1280. (Pubitemid 20195640)
11. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010; 28(6): e91-93.
12. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about antiangiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009; 9: 444.
13. Nelson SJ, Cha S. Imaging glioblastoma multiforme. Cancer J. 2003; 9(2): 134-145.
14. Bendszus M, Warmuth-Metz M, Klein R, et al. MR spectroscopy in gliomatosis cerebri. AJNR Am J Neuroradiol. 2000; 21(2): 375-380. (Pubitemid 30102170)
15. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport. 1991; 2(3): 131-134.
16. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003; 2(5): 497-507.
17. OhJ, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004; 19(5): 546-554. (Pubitemid 38619916)
18. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med. 2003; 49(2): 223-232. (Pubitemid 36159858)
19. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993; 30(6): 672-679. (Pubitemid 23360802)
20. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14(4): 260-264. (Pubitemid 32611437)
21. Kim H, Catana C, Ratai EM, et al. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res. 2011; 71(11): 3745-3752.
22. Hattingen E, Jurcoane A, Bahr O, et al. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1HMRSIand quantitativemagnetic resonance imaging study. Neuro Oncol. 2011; 13(12): 1349-1363.
23. Yang I, AghiMK.Newadvances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009; 6(11): 648-657.
24. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009; 252(1): 182-189.
25. Ringelstein A, Turowski B, Gizewski ER, et al. [Evaluation ofADCmapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle]. Rofo. 2010; 182(10): 868-872.
26. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusionmaps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2012; 67(1): 237-245.
27. Ellingson BM, Cloughesy TF, Lai A, et al. Graded functional diffusion mapdefined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011; 13(10): 1151-1161.
28. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patientswhorespond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2011; 72(2): 402-407.
29. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009; 69(13): 5296-5300.
30. Essock-Burns E, Lupo JM, Cha S, et al. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011; 13(1): 119-131.
31. Radbruch A, Lutz K, Wiestler B, et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2012; 14(2): 222-229.
32. Ellingson BM, Cloughesy TF, Lai A, et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012; 106(1): 111-119.
33. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg. 1996; 84(3): 449-458. (Pubitemid 26062870)
34. Sijens PE, Knopp MV, Brunetti A, et al. 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med. 1995; 33(6): 818-826.
35. Lee PL, Yiannoutsos CT, Ernst T, et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging. 2003; 17(6): 625-633. (Pubitemid 36665865)